New York, USA – August 12, 2020 – IntegrateRNA, the top division of Creative Biogene, is one of the global biotechnology companies specializing in RNA research that has many years of experience in providing products and services to a wide range of genomics researchers in the market, including various types of RNA discovery, analysis, and related bioinformatics services, announced the release of its IncRNA service targeting gene expression and treatment of human disease.
lncRNA has multiple functions and can be identified by genomic and transcriptome methods. More in-depth research is needed to discover more lncRNAs with functional annotations. Although the understanding of the functional role of lncRNA is growing rapidly, the field is still in its infancy, and many problems and challenges need to be resolved urgently. Creative Biogene’s lncRNA expert team can provide a complete and innovative solution to help solve the problems encountered in the research process, and ensure to provide customers with the most reliable and effective research services to best satisfy the research goals.
In order to integrate rapid scientific progress and new data to promote lncRNA research, IntegrateRNA has developed a lncRNA array service suitable for humans and rodents to provide the latest, more comprehensive and reliable lncRNA in samples used in biological sciences test methods, which is also a practical long-term non-coding RNA analysis platform with high sensitivity and specificity for medical research. IntegrateRNA provides complete lncRNA array analysis services from RNA sample preparation to data analysis.
IntegrateRNA has successfully embedded the CRISPR/Cas9 system into RNA research to support the research of specific projects. Recently, experts have introduced a customized lncRNA knockout service ranging from strategy design to the final stable cell line through the CRISPR/Cas9 system, which can help customers construct lncRNA libraries and knock out lncRNA genes.
Based on its experience in the field of lncRNA, IntegrateRNA provides customers with a comprehensive lncRNA pull-down service, from the initial experimental design to the final identification of interacting molecules. Its experienced scientists and advanced technology enable this RNA company to provide consistent and high-quality data in a cost-effective manner. IntegrateRNA uses LC-MS to identify the captured protein complex, and then screens the specificity of the protein interacting with the target lncRNA.
“IntegrateRNA is a leading global biotechnology company dedicated to providing genetic researchers with the most comprehensive professional RNA products and services for basic research, drug development and clinical research.” said Marcia Brady, the marketing director of Creative Biogene, she also added, “We guarantee to provide our clients with the most reliable and effective research services to best match your research goals with the shortest turnaround time and lower prices.”
IntegrateRNA, as the division of Creative Biogene that holds a leading position in providing complete solutions for RNA research, has years of experience in next-generation sequencing and develops microarray platforms that enable researchers to explore the world of RNA on an unprecedented scale, and mapping all RNAs involved in cell life programs, human diseases, and drug discovery.